The Endocrine Society's Clinical Practice Guideline on pharmacological management of obesity recommends considering AOMs for patients who experience weight regain after bariatric surgery, particularly when lifestyle modifications prove insufficient
Farella, I., Panza, R., Capozza, M
Its mechanism involves specific engagement of AMY1R and AMY3R in hindbrain and hypothalamic circuits that regulate energy homeostasis, leading to preferential fat mass reduction and altered hypothalamic gene expression profiles [2]
The model follows the category shape: a licensed provider evaluates you virtually and, when appropriate, issues a prescription routed to a retail pharmacy for FDA-approved brand products or a 503A compounding pharmacy for compounded semaglutide or tirzepatide, with ongoing follow-up
Offers third-party manufacturing Franchise
Am J Physiol Gastrointest Liver Physiol 279:G426-436